Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

This data presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts. Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts. Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made. Provisional data presented will be updated on a monthly basis as additional records are received. For more information please visit: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Content:

Over 93,000 people will die from drug overdoses in the United States in 2020, according to escalating death rates in recent years. Fentanyl and other synthetic opioids are a significant factor in the rise. The misuse of stimulants, benzodiazepines, and narcotic prescription drugs also contributes. A multimodal strategy is needed to address the problem, including better prescription drug monitoring schemes, more access to addiction treatment, and harm reduction tactics.

Context:

In recent years, the number of drug overdose deaths in the United States has become a significant public health concern. The misuse of prescription medications, the usage of synthetic opioids, and the lack of access to addiction treatment are a few of the causes contributing to the surge in drug overdose deaths. The problem emphasizes the requirement for successful treatments and preventative plans, as well as the necessity to deal with the social determinants of health that influence substance misuse.

Drugs prevention precautions:

Here are some drug prevention precautions that are important to keep in mind:

• Properly dispose of unused medication to prevent them from being misused.
• Keep prescription medication in a secure location and only take it as directed by a healthcare provider.
• Avoid using drugs, including prescription medication, that is not prescribed to you.
• Educate yourself and others on the risks and consequences of drug use.
• Seek help for substance abuse or addiction from a healthcare professional or addiction treatment provider.
• Practice harm reduction strategies, such as carrying naloxone for opioid overdoses.
• Address underlying mental health issues and social determinants of health that may contribute to substance abuse. # Acknowledgment: This Dataset was created from https://rb.gy/vk7kh/. if you want to learn more, you can visit the URL address. Cover Photo by https://wallpapercave.com/ # Dataset Glossary( Column-Wise) INDICATOR - name or code of the indicator PANEL - category or panel the indicator belongs to PANEL_NUM - numeric code for the panel UNIT - the unit of measurement for the indicator UNIT_NUM - numeric code for the unit of measurement STUB_NAME - name or code for the rows in the table STUB_NAME_NUM - numeric code for the row names STUB_LABEL - label or description for the row names STUB_LABEL_NUM - numeric code for the stub labels YEAR - year or time period for the data being measured YEAR_NUM - numerical representation of the year AGE - age group being measured AGE_NUM - numerical representation of the age group ESTIMATE - the estimated number of drug overdose deaths for the given year and age group FLAG - an indicator of data quality or reliability, such as a missing or suppressed estimate

To: State, territorial, tribal, and local policymakers and administrators of agencies and programs focused on child, youth, and family health and well-being Dear Colleagues, Thank you for your work to support children, youth, and families. Populations served by Administration for Children and Families (ACF)-funded programs — including victims of trafficking or violence, those who are unhoused, and young people and families involved in the child welfare system — are often at particularly high risk for substance use and overdose. A variety of efforts are underway at the federal, state, and local levels to reduce overdose deaths. These efforts focus on stopping drugs from entering communities, providing life-saving resources, and preventing drug use before it starts. Initiatives across the country are already saving lives: the overdose death rate has declined over the past year but remains too high at 32.6 per 100,000 individuals. Fentanyl, a powerful synthetic opioid, raises the risk of overdose deaths because even a tiny amount can be deadly. Young people are particularly at risk for fentanyl exposure, driven in part by widespread availability of counterfeit pills containing fentanyl that are marketed to youth through social media. While overdose deaths among teens have recently begun to decline, there were 6,696 deaths among adolescents and young adults in 2022 (the latest year with data available)[1], making unintentional drug overdose the second leading cause of death for youth ages 15—19 and the first leading cause of death among young adults ages 20-24.[2] Often these deaths happen with others nearby and can be prevented when opioid overdose reversal medications, like naloxone, are administered in time. CDC’s State Unintentional Drug Overdose Reporting System dashboard shows that in all 30 jurisdictions with available data, 64.7% of drug overdose deaths had at least one potential opportunity for intervention.[3] Naloxone rapidly reverses an overdose and should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It can be given as a nasal spray. Studies show that naloxone administration reduces death rates and does not cause harm if used on a person who is not overdosing on opioids. States have different policies and regulations regarding naloxone distribution and administration. Forty-nine states and the District of Columbia have Good Samaritan laws protecting bystanders who aid at the scene of an overdose.[4] ACF grant recipients and partners can play a critical role in reducing overdose deaths by taking the following actions: Stop Overdose Now (U.S. Centers for Disease Control and Prevention) Integrating Harm Reduction Strategies into Services and Supports for Young Adults Experiencing Homelessness (PDF) (ACF) Thank you for your dedication and partnership. If you have any questions, please contact your local public health department or state behavioral health agency. Together, we can meaningfully reduce overdose deaths in every community. /s/ Meg Sullivan Principal Deputy Assistant Secretary [1] Products - Data Briefs - Number 491 - March 2024 [2] WISQARS Leading Causes of Death Visualization Tool [3] SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC [4] Based on 2024 report from the Legislative Analysis and Public Policy Association (PDF). Note that the state of Kansas adopted protections as well following the publication of this report. Metadata-only record linking to the original dataset. Open original dataset below.

All opioids are chemically related and interact with opioid receptors on nerve cells in the body and brain. Opioid pain relievers can be misused (taken in a different way or in a larger quantity than prescribed, or taken without a doctor’s prescription). Regular use - even as prescribed by a doctor - can lead to dependence and, when misused, opioid pain relievers can lead to addiction, overdose incidents, and deaths. The National Institute on Drug Abuse collects and analyzes data about deaths from opioid abuse. This data set reports on data from 1999-2019.

Data Dictionary

ObjectiveU.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use resulting from the societal disruptions related to the coronavirus (COVID-19) pandemic. A competing explanation is that higher overdose deaths and ED visits may have reflected a continuation of pre-pandemic trends in synthetic-opioid deaths, which began to rise in mid-2019. We assess the evidence on whether increases in overdose deaths and ED visits are likely to be related primarily to the COVID-19 pandemic, increased synthetic-opioid use, or some of both.MethodsWe use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015–2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 states; and ED visit data for 181 EDs in 24 states staffed by a national ED physician staffing group (January 2016-June 2022). We study drug overdose deaths per 100,000 persons during the pandemic period, and ED visits for drug overdoses, in both cases compared to predicted levels based on pre-pandemic trends.ResultsMortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is well-predicted by models that extrapolate pre-pandemic trends for rolling 12-month mortality to the pandemic period. Placebo analyses (which assume the pandemic started earlier or later than March 2020) do not provide evidence for a change in trend in or soon after March 2020. State-level analyses of actual mortality, relative to mortality predicted based on pre-pandemic trends, show no consistent pattern. The state-level results support state heterogeneity in overdose mortality trends, and do not support the pandemic being a major driver of overdose mortality.ED visits. ED overdose visits rose during our sample period, reflecting a worsening opioid epidemic, but rose at similar rates during the pre-pandemic and pandemic periods.ConclusionThe reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely explained by a continuation of pre-pandemic trends toward rising synthetic-opioid deaths, principally fentanyl, that began in mid-to-late 2019. We do not find evidence supporting the pandemic as a major driver of rising mortality. Policymakers need to directly address the synthetic opioid epidemic, and not expect a respite as the pandemic recedes.

Background: Methamphetamine-related deaths have been rising along with those involving synthetic opioids, mostly fentanyl and fentanyl analogs (FAs). However, the extent to which methamphetamine involvement in deaths differs from those changes occurring in synthetic opioid involvement is unknown. Objectives: To determine the patterns and temporal changes in methamphetamine-related deaths with and without other drug involvement. Methods: Data from all methamphetamine-related deaths in West Virginia from 2013 to 2018 were analyzed. Quasi-Poisson regression analyses over time were conducted to compare the rates of change in death counts among methamphetamine and fentanyl//FA subgroups. Results: A total of 815 methamphetamine-related deaths were analyzed; 572 (70.2%) were male and 527 (64.7%) involved an opioid. The proportion of methamphetamine only deaths stayed relatively flat over time although the actual numbers of deaths increased. Combined fentanyl/FAs and methamphetamine were involved in 337 deaths (41.3%) and constituted the largest increase from 2013 to 2018. The modeling of monthly death counts in 2017–2018 found that the average number of deaths involving fentanyl without methamphetamine significantly declined (rate of change −0.025, p < .001), while concomitant fentanyl with methamphetamine and methamphetamine only death counts increased significantly (rate of change 0.056 and 0.057, respectively, p < .001). Conclusions: Fentanyl and FAs played an increasingly significant role in methamphetamine-related deaths. The accelerating number of deaths involving fentanyl/FAs and methamphetamine indicates the importance of stimulants and opioids in unintentional deaths. Comprehensive surveillance efforts should continue to track substance use patterns to ensure that appropriate prevention programs are undertaken.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Source: Office of State Medical Examiners (OSME), Rhode Island Department of Health (RIDOH)

Source: Office of State Medical Examiners (OSME), Rhode Island Department of Health (RIDOH) Note: Data are limited to opioid-involved accidental drug overdose deaths. Counts may not add to annual totals due to missing case information. Percentages may not add to 100 due to rounding. Percentages are displayed as decimals. Prescription medications include prescription opioids such as oxycodone, hydrocodone, and benzodiazepines. Illicit drugs include substances such as heroin, illicit fentanyl, and cocaine.

Total number of accidental overdose deaths in Pierce County

The following dataset is the World Drug Report 2021 produced by the United Nations Office on Drugs and Crime. https://www.unodc.org/unodc/en/data-and-analysis/wdr2021_annex.html

The Executive Summary: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf

Special points of interest from the report: - Cannabis has come to be seen as less risky by adolescents from 1995 to 2019, but the herb potency has increased 4x in that time period. - Web-based sales have increased dramatically. - Number of drug users in Africa is projected to rise by 40 per cent by 2030, based on expected population growth in the 15-64 demographic. - Drug markets quickly recovered after the onset of the pandemic, but some trafficking dynamics have been accelerated during Covid-19 - Non-medical use of cannabis and sedatives has increased globally during the pandemic

On Opioids specifically: - The two pharmaceutical opioids most commonly used to treat people with opioid use disorders, methadone and buprenorphine, have become increasingly accessible over the past two decades. The amount available for medical use has increased sixfold since 1999, from 557 million daily doses in that year to 3,317 million by 2019. - The amounts of fentanyl and its analogues seized globally have risen rapidly in recent years, and by more than 60 per cent in 2019 compared with a year earlier. Overall, these amounts have risen more than twenty-fold since 2015. The largest quantities were seized in North America. - Elsewhere in the world, other pharmaceutical opioids (codeine and tramadol) predominate. Over the period 2015–2019, the largest quantities of tramadol seized were reported in West and Central Africa; they accounted for 86 per cent of the global total. Codeine was intercepted in large quantities in Asia, often in the form of diverted cough syrups. - Almost 50,000 people died from overdose deaths attributed to opioids in the United States in 2019, more than double the 2010 figure. By comparison, in the European Union, the figure for all drug-related overdoses (mostly relating to opioid use) stood at 8,300 in 2018, despite the larger population. - However, the opioid crisis in North America is evolving. The number of deaths attributed to heroin and the non-medical use of pharmaceutical opioids such as oxycodone or hydrocodone has been declining over the past five years. - The crisis is now driven mainly by overdose deaths attributed to synthetic opioids such as fentanyl and its analogues. Among the reasons for the large number of overdose deaths attributed to fentanyls is that the lethal doses of them are often small when compared with other opioids. Fentanyl is up to 100 times more potent than morphine. - The impact of fentanyl is illustrated even further by the fact that more than half of the deaths attributed to heroin also involve fentanyls. Synthetic opioids also contribute significantly to the increased number of overdose deaths attributed to cocaine and other psychostimulants, such as methamphetamine.

Context

The rate of overdose deaths in Connecticut increased from 9.9 per 100,000 residents in 2012 to 28.5 per 100,000 residents in 2018-a 221 % increase-with the majority occurring among persons aged 35-64 (65.3 %), men (73.9 %), and non-Hispanic whites (78.5 %). Among deaths involving fentanyl, the overall deaths escalated from 5.2 deaths per 100,000 residents in 2015 to 21.3 deaths per 100,000 residents in 2018 and more than 50% of these fentanyl-related deaths involved polysubstance use.

Inspiration

• To examine trends in polysubstance detection associated with drug-related overdose deaths

Fatal drug overdoses have involved both xylazine and fentanyl. Xylazine is a non-opioid substance used in veterinary medicine. This study aimed to model changes in fatal xylazine-involved drug overdose deaths from 2019 to 2023 in Connecticut using overdose death data from the Office of the Chief Medical Examiner. Xylazine-involved drug overdose fatality rates were calculated by number of deaths per year per 100,000 population from 2019 to 2023. We used joinpoint regression modeling to evaluate quarterly overdose rates across age, number of drugs, and drug types with a significance level of p 

In recent years, synthetic opioids have emerged as a predominant cause of drug-overdose-related fatalities, causing the “opioid crisis.” To design safer therapeutic agents, we accidentally discovered μ-opioid receptor (MOR) antagonists based on fentanyl with a relatively uncomplicated chemical composition that potentiates structural modifications. Here, we showed the development of novel atropisomeric fentanyl analogues that exhibit more potent antagonistic activity against MOR than naloxone, a morphinan MOR antagonist. Derivatives displaying stable axial chirality were synthesized based on the amide structure of fentanyl. The aS- and aR-enantiomers exerted antagonistic and agonistic effects on the MOR, respectively, and each atropisomer interacted with the MOR by assuming a distinct binding mode through molecular docking. These findings suggest that introducing atropisomerism into fentanyl may serve as a key feature in the molecular design of future MOR antagonists to help mitigate the opioid crisis.

Number and percentage of participants who experienced apnea that required stimulation (i.e. persistent apnea).

Maximum change from pre-fentanyl baseline in oxygen saturation (%) in opioid-tolerant patients.

Participant demographic and clinical characteristics.